FDA authorized Vela Diagnostics’ Sentosa SQ HIV Genotyping Assay
The Food and Drug Administration has given the go-ahead to what it calls the first next-generation sequencing test for detecting mutations that enable the most common strain of HIV to become immune to drugs. The FDA said that it had authorized
PredictImmune signs agreement with Theradiag to Commercialise PredictSURE IBD in French speaking Europe
PredictImmune, developers of pioneering prognostic tools for guiding treatment options in immune-mediated diseases, confirmed that it has entered into a commercial partnership with Theradiag, a pioneering European diagnostic company specialising in in vitro diagnostics and theranostics for autoimmune diseases and
PierianDx raises $27M in Series B to ‘democratize’ next-generation sequencing
The startup describes its software as providing clinical labs with more streamlined and accurate analysis, interpretation and reporting for accelerating personalized medicine programs. A startup that aims to provide a software-as-a-service platform to allow genomic sequencing as a standard of
HTG Molecular Diagnostics Announces Completion of $22.5 Million Aggregate Financing
HTG Molecular Diagnostics Announces Completion of $22.5 Million Aggregate Financing, Consisting of $19.0 Million Public Offering of Common Stock, Including the Exercise in Full of the Underwriter’s Option to Purchase Additional Shares, and $3.5 Million Concurrent Private Placement. HTG is focused
Prescient gets FDA breakthrough status for colorectal cancer test
Prescient Metabiomics has received FDA breakthrough status for its non-invasive colorectal cancer test. The test, called LifeKit Prevent, identifies microbial DNA and RNA biomarkers associated with the new, abnormal growth of tissue in the gastrointestinal tract. By detecting these changes